Latest Health News
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell…
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
The Ninth Circuit Orders California to Respond concerning its Mandatory DEI Indoctrination in Continuing Medical Education Courses, According to the Association of American Physicians and Surgeons
TUCSON, Ariz., Sept. 04, 2025 (GLOBE NEWSWIRE) -- On September 2, the…
Avania Strengthens Leadership Team with Appointment of Four New Executives
BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania, the…
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
September 03, 2025 17:17 ET | Source: Senseonics Holdings, Inc. CGM commercial…
Sotera Health Announces Secondary Offering of Common Stock
September 03, 2025 16:57 ET | Source: Sotera Health Services, LLC CLEVELAND,…
UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc. HIGH POINT,…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
